OKLAHOMA CITY–(BUSINESS WIRE)–VADOVATIONS, Inc., a company developing miniaturized cardiac assist pumps offering best-in-class blood handling properties, high performance and low cost, today announces an agreement with a strategic partner to both invest in the Company and develop a percutaneous endovascular delivery system for VADovations’ novel cardiac assist pump for long-term use in patients suffering with heart failure. This next-generation technology is designed to avoid open surgical implantation while addressing the limitations of current blood pumps.
Kurt Dasse PhD, president of VADovations, says, “Advanced heart failure patients will appreciate and benefit from reduced trauma and improved quality of life from less invasive cardiac assist device implant techniques. Combining best-in-class heart pumps with novel deployment technology will be well-received by clinicians and patients. This type of innovation supports our mission to overcome the limitations of current and emerging devices. We are proud to work with our strategic partner to enable the endovascular deployment of VADovations’ ultra-miniature cardiac assist pump uniquely designed for enhanced safety and cost-effectiveness. This approach eliminates the need for extensive open-heart surgery, which is today’s standard of care.”
Heart failure is a serious problem affecting 500,000 patients annually in the US alone. Left untreated, it is more fatal than cancer and options are limited as heart failure progresses. Heart transplantation is effective at end-stage but is limited to only 3,500 hearts annually. The growing field of Mechanical Circulatory Support systems offers alternatives for cardiothoracic surgeons and interventional cardiologists.
James Long MD, PhD, a highly recognized heart transplant surgeon and a pioneer in the use of Mechanical Circulatory Support (MCS) for heart failure, explains, “The MCS field needs to reduce the complexity and cost of implanting cardiac assist devices. Improved implant techniques should increase the number of patients who are clinically appropriate candidates for long-term use of cardiac assist devices.”
VADovations maintains an affiliation with INTEGRIS Health, Oklahoma’s largest health care provider, a not-for-profit system that enjoys distinction for innovation, leading-edge medicine and is a member of the Mayo Clinic Care Network. INTEGRIS will use any revenue it receives to support its not-for-profit missions in patient care, education and research.
Northland Capital Markets is acting as financial advisor to VADovations.
Revolutionizing cardiac support technology and the treatment of heart failure, VADovations is developing ultra-miniaturized blood pumps designed for minimally invasive and percutaneous, endovascular deployment while addressing the total spectrum of advanced heart failure therapy with the best possible quality and cost-effectiveness. Contact: firstname.lastname@example.org; Visit https://vadovations.com/.
Safe Harbor Statement
Statements in this press release are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements.
201.641.1911 x 54 Contact: